Description
Bimekizumab is an investigational humanized IgG1 monoclonal antibody in development for the treatment of moderate to severe plaque psoriasis in adults. Bimekizumab is designed to selectively and directly inhibit both IL-17A and IL-17F, two key cytokines driving the inflammatory process in plaque psoriasis